These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 34289822)

  • 21. Utility of a one-step screening and diagnosis strategy for viremic HCV infection among people who inject drugs in Catalonia.
    Saludes V; Antuori A; Folch C; González N; Ibáñez N; Majó X; Colom J; Matas L; Casabona J; Martró E;
    Int J Drug Policy; 2019 Dec; 74():236-245. PubMed ID: 31706159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High hepatitis C incidence in relation to prescription opioid injection and poly-drug use: Assessing barriers to hepatitis C prevention.
    Puzhko S; Roy É; Jutras-Aswad D; Artenie AA; Fortier E; Zang G; Bruneau J
    Int J Drug Policy; 2017 Sep; 47():61-68. PubMed ID: 28666636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of HIV and other infections and injection behaviours among people who inject drugs in Addis Ababa, Ethiopia.
    Demissie M; Johnston LG; Muleta M; Desyebelew D; Belete W; G/Egxiabehre A; Gezahegn N; Kassa D; Aseffa Y
    Afr J AIDS Res; 2018 Sep; 17(3):259-264. PubMed ID: 30319040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C virus prevalence and associated risk factors among Indigenous Australians who inject drugs.
    Doyle M; Maher L; Graham S; Wand H; Iversen J
    Aust N Z J Public Health; 2018 Feb; 42(1):52-56. PubMed ID: 29168317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis C continuum of care and utilization of healthcare and harm reduction services among persons who inject drugs in Seattle.
    Tsui JI; Miller CM; Scott JD; Corcorran MA; Dombrowski JC; Glick SN
    Drug Alcohol Depend; 2019 Feb; 195():114-120. PubMed ID: 30611979
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Access to and use of health and social services among people who inject drugs in two urban areas of Mozambique, 2014: qualitative results from a formative assessment.
    Dengo-Baloi L; Boothe M; Semá Baltazar C; Sathane I; Langa DC; Condula M; Ricardo H; Inguane C; Teodoro E; Gouveia L; Raymond HF; Horth R
    BMC Public Health; 2020 Jun; 20(1):975. PubMed ID: 32571365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Examining risk behavior and syringe coverage among people who inject drugs accessing a syringe services program: A latent class analysis.
    Bartholomew TS; Tookes HE; Bullock C; Onugha J; Forrest DW; Feaster DJ
    Int J Drug Policy; 2020 Apr; 78():102716. PubMed ID: 32146348
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cross-border injection drug use and HIV and hepatitis C virus seropositivity among people who inject drugs in San Diego, California.
    Horyniak D; Wagner KD; Armenta RF; Cuevas-Mota J; Hendrickson E; Garfein RS
    Int J Drug Policy; 2017 Sep; 47():9-17. PubMed ID: 28683432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High prevalence of HIV, HBsAg and anti-HCV positivity among people who injected drugs: results of the first bio-behavioral survey using respondent-driven sampling in two urban areas in Mozambique.
    Semá Baltazar C; Horth R; Boothe M; Sathane I; Young P; Chitsondzo Langa D; Condula M; Ricardo H; Dengo Baloi L; Cummings B; Schaad N; Gouveia L; Teodoro E; Raymond HF
    BMC Infect Dis; 2019 Dec; 19(1):1022. PubMed ID: 31791273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland.
    Fraser H; Mukandavire C; Martin NK; Goldberg D; Palmateer N; Munro A; Taylor A; Hickman M; Hutchinson S; Vickerman P
    Addiction; 2018 Nov; 113(11):2118-2131. PubMed ID: 29781207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A cross-sectional study of hepatitis C prevalence and correlates among persons who inject drugs in rural and non-rural communities.
    Barranco MA; Rosenberg ES; Flanigan C; Shufelt S; Bruce EM; Wilberschied LA; Parker MM; Duncan E; Udo T
    J Viral Hepat; 2022 Nov; 29(11):994-1003. PubMed ID: 35925950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence-based and guideline-concurrent responses to narratives deferring HCV treatment among people who inject drugs.
    Childs E; Assoumou SA; Biello KB; Biancarelli DL; Drainoni ML; Edeza A; Salhaney P; Mimiaga MJ; Bazzi AR
    Harm Reduct J; 2019 Feb; 16(1):14. PubMed ID: 30744628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis C testing and treatment uptake among young people who use opioids in New York City: A cross-sectional study.
    Kapadia SN; Katzman C; Fong C; Eckhardt BJ; Guarino H; Mateu-Gelabert P
    J Viral Hepat; 2021 Feb; 28(2):326-333. PubMed ID: 33141503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011.
    Iversen J; Grebely J; Topp L; Wand H; Dore G; Maher L
    J Viral Hepat; 2014 Mar; 21(3):198-207. PubMed ID: 24438681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An urgent need to scale-up injecting drug harm reduction services in Tanzania: prevalence of blood-borne viruses among drug users in Temeke District, Dar-es-Salaam, 2011.
    Bowring AL; Luhmann N; Pont S; Debaulieu C; Derozier S; Asouab F; Toufik A; van Gemert C; Dietze P; Stoove M
    Int J Drug Policy; 2013 Jan; 24(1):78-81. PubMed ID: 23036650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rural risk environments for hepatitis c among young adults in appalachian kentucky.
    Cloud DH; Ibragimov U; Prood N; Young AM; Cooper HLF
    Int J Drug Policy; 2019 Oct; 72():47-54. PubMed ID: 31113713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug checking in the fentanyl era: Utilization and interest among people who inject drugs in San Diego, California.
    Bailey K; Abramovitz D; Artamonova I; Davidson P; Stamos-Buesig T; Vera CF; Patterson TL; Arredondo J; Kattan J; Bergmann L; Thihalolipavan S; Strathdee SA; Borquez A
    Int J Drug Policy; 2023 Aug; 118():104086. PubMed ID: 37295217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention knowledge, risk behaviours and seroprevalence among nonurban injectors of southwest Connecticut.
    Grau LE; Zhan W; Heimer R
    Drug Alcohol Rev; 2016 Sep; 35(5):628-36. PubMed ID: 27073014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis C Virus seroconversion among persons who inject drugs in relation to primary care physician visiting: The potential role of primary healthcare in a combined approach to Hepatitis C prevention.
    Artenie AA; Roy É; Zang G; Jutras-Aswad D; Bamvita JM; Puzhko S; Daniel M; Bruneau J
    Int J Drug Policy; 2015 Oct; 26(10):970-5. PubMed ID: 26005038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-Risk Injection-Related Practices Associated with anti-HCV Positivity among Young Adults Seeking Services in Three Small Cities in Wisconsin.
    Rogers-Brown J; Sublett F; Canary L; Rein DB; Bhat M; Thompson WW; Vellozzi C; Asher A
    Subst Use Misuse; 2022; 57(5):665-673. PubMed ID: 35240921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.